Ascentage Pharma (AAPG) CMO awarded options, RSUs and reports new share holdings
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Ascentage Pharma Group International Chief Medical Officer Yifan Zhai reported multiple equity compensation transactions involving options, restricted stock units (RSUs), and related ordinary shares of AAPG.
On May 20, 2026, entities associated with Zhai received several awards. These included options for 298,194 ordinary shares held indirectly by a spouse at an exercise price of $6.58 per share, options for 214,988 ordinary shares directly at $6.58 per share, and options for 103,364 ordinary shares directly at $8.12 per share. Multiple RSU grants were also recorded, including 298,195, 214,999, 103,365, 95,575, and 92,746 RSUs tied to one ordinary share each upon vesting.
On May 21, 2026, RSUs vested and were converted into ordinary shares. Indirectly through a spouse, 95,575 RSUs vested into the same number of ordinary shares, resulting in 1,193,569 indirectly held ordinary shares. Directly, 92,746 RSUs vested into ordinary shares, bringing direct ordinary share holdings to 405,280 shares. No sales of shares were reported; all transactions were classified as acquisitions, grants, or exercises. Additional indirect ordinary share holdings of 22,054,131 shares held by HealthQuest Pharma Limited and 14,089,111 shares held by Dajun Yang Dynasty Trust are attributed to related entities, with beneficial ownership disclaimed except for any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
188,321 shares exercised/converted
Mixed
14 txns
Insider
Zhai Yifan
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted stock units | 92,746 | $0.00 | -- |
| Exercise | Restricted stock units | 95,575 | $0.00 | -- |
| Exercise | Ordinary Shares | 92,746 | $0.00 | -- |
| Exercise | Ordinary Shares | 95,575 | $0.00 | -- |
| Grant/Award | Restricted stock units | 103,365 | $0.00 | -- |
| Grant/Award | Restricted stock units | 214,999 | $0.00 | -- |
| Grant/Award | Options | 214,988 | $0.00 | -- |
| Grant/Award | Options | 103,364 | $0.00 | -- |
| Grant/Award | Restricted stock units | 92,746 | $0.00 | -- |
| Grant/Award | Restricted stock units | 95,575 | $0.00 | -- |
| Grant/Award | Restricted stock units | 298,195 | $0.00 | -- |
| Grant/Award | Options | 298,194 | $0.00 | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Restricted stock units — 0 shares (Direct, null);
Restricted stock units — 0 shares (Indirect, By Spouse);
Ordinary Shares — 405,280 shares (Direct, null);
Ordinary Shares — 1,193,569 shares (Indirect, See Footnote (2));
Options — 214,988 shares (Direct, null);
Options — 298,194 shares (Indirect, By Spouse)
Footnotes (1)
- Shares held by Dajun Yang Dynasty Trust, of which the Reporting Person's spouse is the investment advisor. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Shares held by Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Shares held by HealthQuest Pharma Limited, an entity controlled by the Reporting Person. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Each restricted stock unit (the "RSUs") represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on November 26, 2026, 2027, 2028 and 2029 and have no expiration date. The RSUs vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and have no expiration date. The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and expire ten years from the date of grant. The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on November 26, 2026, 2027, 2028 and 2029 and expire ten years from the date of grant. The RSUs vested on 05/21/2026 and had no expiration date. Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person on 05/20/2026. Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person's spouse on 05/20/2026.
Key Figures
RSUs vested indirectly: 95,575 RSUs
RSUs vested directly: 92,746 RSUs
Direct ordinary shares after transactions: 405,280 shares
+5 more
8 metrics
RSUs vested indirectly
95,575 RSUs
Converted into 95,575 ordinary shares on May 21, 2026
RSUs vested directly
92,746 RSUs
Converted into ordinary shares on May 21, 2026
Direct ordinary shares after transactions
405,280 shares
Direct holdings following RSU vesting
Indirect ordinary shares via spouse
1,193,569 shares
Indirect ordinary share holdings after RSU vesting
Options via spouse
298,194 options at $6.58
Option grant on May 20, 2026, exercisable into ordinary shares
Direct options at $6.58
214,988 options at $6.58
Direct option grant on May 20, 2026
Direct options at $8.12
103,364 options at $8.12
Direct option grant on May 20, 2026
Indirect HealthQuest holdings
22,054,131 shares
Ordinary shares held by HealthQuest Pharma Limited
Key Terms
Restricted stock units, pecuniary interest, Section 16, exercise price, +2 more
6 terms
Restricted stock units financial
"Each restricted stock unit (the "RSUs") represents a contingent right to receive one Ordinary Share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
pecuniary interest financial
"disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein"
Section 16 regulatory
"shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
exercise price financial
"The exercise price of the options is in HKD and the exercise price included in the table"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest financial
"The RSUs vest in four equal increments on November 26, 2026, 2027, 2028 and 2029"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
grant, award, or other acquisition financial
"transaction_code_description": "Grant, award, or other acquisition""
FAQ
What insider transactions did Ascentage Pharma (AAPG) report for Yifan Zhai?
The filing shows Chief Medical Officer Yifan Zhai had equity compensation activity, including stock option and RSU grants on May 20, 2026, and RSU vesting into ordinary shares on May 21, 2026, with no reported share sales or open-market purchases.
What stock option awards did Ascentage Pharma (AAPG) grant to Yifan Zhai?
On May 20, 2026, entities associated with Yifan Zhai received options over 298,194 ordinary shares indirectly via a spouse at $6.58 per share, plus direct options over 214,988 shares at $6.58 and 103,364 shares at $8.12, all exercisable into ordinary shares.
What indirect Ascentage Pharma (AAPG) holdings are associated with Yifan Zhai?
Indirect holdings include 1,193,569 ordinary shares via a spouse after RSU vesting, plus 22,054,131 ordinary shares held by HealthQuest Pharma Limited and 14,089,111 shares held by Dajun Yang Dynasty Trust, with beneficial ownership disclaimed except for any pecuniary interest.